靶向 ErbB2/HER2 的 CAR-NK 细胞在重现肿瘤进展的类器官模型中清除乳腺癌细胞
ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.
嵌合抗原受体工程化 NK 细胞在过继性肿瘤免疫治疗中展现出前景。
67.8分
★★★☆☆
ALL SOURCES
ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.
嵌合抗原受体工程化 NK 细胞在过继性肿瘤免疫治疗中展现出前景。
Ablation of Cbl-b in ROBO1 CAR-NK92 Cells Enhances Their Antitumor Efficacy.
体外实验中,在效靶比(E:T)为0.1:1时,ROBO1 CAR-NK92-Cbl-b-KO细胞(50.55%)与ROBO1阳性T47D靶细胞共培养3小时后,其细胞杀伤活性显著高于ROBO1 CAR-NK92(34.10%)、NK92-Cbl-b-KO(22.22%)和亲本NK-92细胞(3.28%)。
CAR-T/NK/M-based combination therapies in cancer: A comprehensive review.
CAR-T(CAR-T)细胞疗法与其他治疗或药物联合应用,是肿瘤免疫治疗领域的突破性进展。
共 3 条
MEMBER ACCOUNT
登录成功会直接打开下一页。